Maravai LifeSciences (NASDAQ:MRVI) Stock Rating Lowered by Robert W. Baird

Robert W. Baird downgraded shares of Maravai LifeSciences (NASDAQ:MRVI) from an outperform rating to a neutral rating in a research report released on Wednesday, MarketBeat reports. They currently have $3.00 price target on the stock, down from their previous price target of $9.00.

A number of other analysts also recently weighed in on MRVI. Royal Bank of Canada dropped their target price on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Wolfe Research initiated coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. Guggenheim initiated coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating for the company. William Blair restated a “market perform” rating on shares of Maravai LifeSciences in a research report on Friday, November 8th. Finally, The Goldman Sachs Group downgraded Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their target price for the stock from $7.00 to $4.25 in a research report on Thursday, December 5th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Maravai LifeSciences presently has an average rating of “Hold” and an average price target of $9.46.

Maravai LifeSciences Stock Up 5.6 %

Shares of NASDAQ MRVI opened at $3.22 on Wednesday. Maravai LifeSciences has a 12 month low of $2.93 and a 12 month high of $11.56. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. The firm has a market capitalization of $813.14 million, a price-to-earnings ratio of -1.96 and a beta of -0.08. The business has a 50-day moving average of $4.84 and a 200-day moving average of $6.48.

Insider Buying and Selling at Maravai LifeSciences

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the sale, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of MRVI. Performa Ltd US LLC lifted its position in Maravai LifeSciences by 614.3% in the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock valued at $27,000 after purchasing an additional 4,300 shares during the last quarter. FNY Investment Advisers LLC raised its holdings in shares of Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock valued at $38,000 after acquiring an additional 6,000 shares in the last quarter. Venturi Wealth Management LLC bought a new position in shares of Maravai LifeSciences during the third quarter valued at approximately $47,000. Farther Finance Advisors LLC raised its holdings in shares of Maravai LifeSciences by 3,541.4% during the fourth quarter. Farther Finance Advisors LLC now owns 10,196 shares of the company’s stock valued at $56,000 after acquiring an additional 9,916 shares in the last quarter. Finally, Cibc World Markets Corp bought a new position in shares of Maravai LifeSciences during the fourth quarter valued at approximately $56,000. Institutional investors own 50.25% of the company’s stock.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.